*The following is for informational purposes only and should not be taken as medical advice. People living with ALS should consult with their doctors for advice regarding Radicava or any other medical treatment. ALS Association chapters and staff should refer individuals to their healthcare providers for medical advice.
Where can I get the most up-to-date information about Radicava?
Patients should call Searchlight for the most up-to-date Radicava information.
Monday-Friday, 8AM 8PM ET
Effective August 1, 2019, The Searchlight Support® portal will no longer be available for online enrollments and ordering. We apologize for any inconvenience this may cause. Please utilize the program forms available on radicava.com/hcp.
Mitsubishi Tanabe Pharma America
Go to www.Radicava.com to provide an email address, which will enable the patient to receive updates on availability from MTPA.
What is Radicava?
Radicava™ (edaravone) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) to treat people with amyotrophic lateral sclerosis (ALS).1 In clinical trials, some people given Radicava showed significantly less decline in physical function compared to placebo as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), a validated rating instrument for monitoring the progression of disability in patients with ALS.1,2
What will Radicava do for people with ALS? How meaningful of a treatment is it?
Although Radicava is not a cure, it may be an important advance in helping people live with the disease. Because people with ALS experience varying rates of progression, slowing the decline of that loss of function is important. Depending on a person’s level of function when they begin treatment, the impact Radicava demonstrated in clinical trials could translate into potentially helping people preserve function longer.1
What is the recommended dose of Radicava?
Radicava is administered via intravenous infusion. According to the Prescribing Information, Radicava is administered in 28-day cycles by intravenous infusion. It takes 60 minutes to receive each 60 mg dose.1
For the initial cycle, the treatment is infused for 14 consecutive days, followed by a two-week drug-free period. All cycles thereafter are infused for 10 days within a 14-day period, followed by a two-week drug-free period.1
What data formed the basis for the FDA approval?
Study MCI186-19 was the pivotal Phase 3 study that evaluated the efficacy and safety of Radicava compared with placebo in 137 people with ALS. In the study, after a 12-week pre-observation period, eligible patients were randomized 1:1 to receive Radicava 60 mg intravenously for 60 minutes or placebo during a six-month double-blind placebo-controlled phase. The primary endpoint for the study was change in the ALSFRS-R score from baseline to six months.1
Were there any issues with safety?
The most common adverse reactions that occurred in more than 10 percent of patients, and were greater than placebo, were bruising (contusion), trouble walking (gait disturbance), headache, inflammation of the skin (eczema) and rash (contact dermatitis).1
How can I get Radicava?
MTPA has outlined several steps you can take now to be able to access Radicava:
MTPA worked to import the medicine into the U.S. as quickly as possible. In addition to manufacturing hundreds of thousands of IV bags ahead of FDA approval, and taking steps to prepare logistics ahead of time, their plan is in place to air-ship Radicava to further accelerate the supply of the medicine from Japan, where it is manufactured.
How does the Searchlight Support program work?
Searchlight Support is a program developed by MTPA designed to help people with ALS, who have been prescribed Radicava, access the medicine and support people once they are taking the medicine. As soon as a patient receives a Radicava prescription and opts in to participate in the program, Searchlight Support will initiate:
For more information, call 1-844-SRCHLGT or 1-844-772-4548. Patients prescribed Radicava should check eligibility requirements for each aspect of MTPA’s patient assistance program as restrictions apply.
How much will Radicava cost me?
The drug’s list price is $1K per infusion, $11K per dosage cycle, which amounts to $146K per year. This does not take into account coverage from insurance or Medicare/Medicaid. The company also says it will offer co-pay assistance for commercially insured patients. For more information please contact Mitsubishi Tanabe Pharma America at www.mt-pharma-america.com or call at 844-772-4548.
What can I do if I don’t have insurance?
MTPA has created a program that provides Radicava at no charge if you do not have insurance and meet income and certain other requirements. The program is available to eligible patients without insurance. MTPA has established the eligibility requirements.
What happens while I’m waiting for Searchlight Support to confirm my insurance?
MTPA has developed a program in which eligible patients may receive Radicava at no charge from MTPA while insurance is making a coverage determination. MTPA has established the eligibility requirements.
Do I need to travel to an ALS Center?
Radicava is given to patients through an IV, and your insurance coverage may determine whether it is administered at an outpatient center, in your home, or another appropriate venue. MTPA will ship Radicava to approved centers for infusion and to specialty pharmacies that can deliver it to patients who will receive treatments in their homes.
What are my options for Radicava infusion sites?
How do I get infusion site location assistance?
Can Searchlight Support help with my transportation?
When you are first prescribed Radicava and opt in to Searchlight Support, your case manager can help you identify transportation options in your area.
What if I have clinical questions about Radicava?
Please contact your healthcare provider if you have clinical questions about Radicava.
Can I take Radicava while on Riluzole?
You should always check with your physician, but Mitsubishi Tanabe Pharma America stated that 90% of the patients involved in its J-19 clinical trial were on Riluzole during the trial, and there is not a contra-indication.
What does “free radical scavenger” mean?
Radicava is designed as a “free radical scavenger” to help the body eliminate excess free radicals, thereby relieving the effects of oxidative stress thus preventing cell damage. See diagram below – RIGHT.
A free radical is an atom or molecule that is a toxic by-product of cells. They have unpaired electrons (see below) that make them highly unstable and reactive. Some normal functions of free radicals are important to cells, such as helping cells eliminate pathogens. However, when free radicals numbers rise too high, cell damage occurs harming the cell and its contents. This reactive cell damage caused by excess free radicals is called oxidative stress. See diagram – LEFT.
One way to combat cell damage caused by free radicals are antioxidants. They add the missing electron back to the free radical. This action stabilizes free radicals, turning them into normal “healthy” molecules, thus preventing cell damage caused by oxidative stress. See diagram – MIDDLE.
In ALS, it is thought that free radicals are not effectively removed, setting off an oxidative stress reaction. Oxidative stress is thought to damage motor neurons, the cells the die in ALS.
What does “RADICAVA caused a slowing in progression of functional loss in ALS patients” mean?
ALS patients saw an slowing in progress of functional disability while taking Radicava demonstrated by a higher score on the ALS Functional Rating Scale Revised (ALSFRS-R) compared to people taking the placebo. This impact observed in trials could translate into potentially helping preserve a person’s function longer, such as feeding oneself or hugging a loved one. However, Radicava does not stop the underlying disease mechanism from occurring in motor neurons (the cells that die in ALS).
1Radicava™ U.S. Prescribing Information.
2Simon, N. G., Turner, M. R., Vucic, S., Al-Chalabi, A., Shefner, J., Lomen-Hoerth, C., & Kiernan, M. C. (2014). Quantifying Disease Progression in Amyotrophic Lateral Sclerosis. Annals of Neurology, 76(5), 643–657.
Articles: Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial The Lancet Neurology.
Comment: Edaravone: a new treatment for ALS on the horizon? Orla Hardiman, Leonard H van den Berg. The Lancet Neurology.